Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ANI Pharmaceuticals ( (ANIP) ) has provided an update.
On May 13, 2026, ANI Pharmaceuticals, Inc. published an updated investor presentation on its website for use in future meetings with investors and analysts, following earnings guidance it discussed on May 8, 2026. The materials detail the company’s use of non-GAAP metrics such as adjusted EBITDA and adjusted diluted EPS, underscoring management’s emphasis on these measures to track operating performance and communicate financial outlook amid ongoing commercialization of products including Cortrophin Gel and ILUVIEN.
The presentation explains how these non-GAAP measures exclude items like stock-based compensation, M&A costs, litigation-related expenses and other infrequent charges, in a bid to provide a clearer view of core profitability. This approach signals ANI’s effort to highlight underlying business trends to the market, which may influence how investors assess its growth prospects, capital needs and the performance of its specialty pharmaceutical portfolio.
The most recent analyst rating on (ANIP) stock is a Buy with a $124.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.
Spark’s Take on ANIP Stock
According to Spark, TipRanks’ AI Analyst, ANIP is a Outperform.
The score is driven primarily by improving financial performance and strong cash generation, reinforced by confident 2026 growth guidance. Technicals are supportive but not fully strong due to the stock remaining below the 200-day average. Valuation appears reasonable on a mid-teens P/E, while margin pressure, elevated growth investment spend, and historical earnings volatility keep the score from being higher.
To see Spark’s full report on ANIP stock, click here.
More about ANI Pharmaceuticals
ANI Pharmaceuticals, Inc. is a specialty pharmaceuticals company focused on developing, manufacturing and marketing branded and generic prescription drugs. Its portfolio and pipeline include therapies such as Purified Cortrophin Gel and ILUVIEN, with a market focus on niche and specialty disease areas in the U.S. healthcare system.
Average Trading Volume: 374,485
Technical Sentiment Signal: Buy
Current Market Cap: $1.81B
Find detailed analytics on ANIP stock on TipRanks’ Stock Analysis page.